Pyxis Oncology (PYXS) Change in Accured Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Change in Accured Expenses data on file, last reported at $552000.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 120.54% year-over-year to $552000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.8 million (down 69.04% YoY) and the FY2025 annual result came in at -$2.8 million, down 69.04% from the prior year.
• Change in Accured Expenses retreated to $552000.0 in Q4 2025 per PYXS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.5 million in Q1 2022 and bottomed at -$13.3 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $464500.0 (2021), against an average of -$77350.0.
• Peak annual rise in Change in Accured Expenses reached 2246.64% in 2022, while the deepest fall reached 2762.07% in 2022.
• Tracing PYXS's Change in Accured Expenses over 5 years: stood at $1.9 million in 2021, then soared by 227.54% to $6.3 million in 2022, then sank by 157.99% to -$3.7 million in 2023, then increased by 26.62% to -$2.7 million in 2024, then soared by 120.54% to $552000.0 in 2025.
• Per Business Quant, the three latest PYXS Change in Accured Expenses figures stand at $552000.0 (Q4 2025), $1.3 million (Q3 2025), and -$3.4 million (Q2 2025).

Peer Comparison